November 20th, 2026Oral SERDs: What Giredestrant Signals for NursesAfter a run of 2026 oral SERD approvals, Erica L. Mayer, MD, MPH, discusses ESR1 testing and a possible adjuvant role for giredestrant.Read more
November 18th, 2026Oral Giredestrant Shifts Care Home: How Nurses Can Support AdherenceErica L. Mayer, MD, MPH, explains what the all-oral giredestrant plus everolimus regimen asks of patients and oncology nurses between clinic visits.Read more
November 17th, 2026Giredestrant Approval: What Nurses Need to Know and What Comes NextThe evERA principal investigator explains ESR1 testing, bradycardia and stomatitis prevention, and oral adherence with giredestrant plus everolimus.Read more
November 17th, 2026FDA Grants Accelerated Approval to Neladalkib in Pretreated ALK+ NSCLCNeladalkib produced response rates of 49% after alectinib and 32% after multiple ALK TKIs plus chemotherapy in the ALKOVE-1 trial.Read more
November 16th, 2026FDA Approves Giredestrant Plus Everolimus for ESR1-Mutated Breast CancerGiredestrant (Wilserdly) plus everolimus nearly doubled median PFS vs standard endocrine therapy plus everolimus in ESR1-mutated disease in evERA.Read more
November 16th, 2026FDA Approves Generic Binimetinib for BRAF-Mutant Melanoma and NSCLCAlembic's generic binimetinib, in 15 mg and 45 mg tablets, is therapeutically equivalent to Mektovi for BRAF-mutant melanoma and NSCLC.Read more
November 16th, 2026FDA Approves Pertuzumab Biosimilar Pebrilzo for HER2+ Breast CancerPertuzumab-qcay is the second FDA-approved biosimilar to Perjeta, but a settlement with Genentech delays its US launch until Q3 2028.Read more
November 16th, 2026FDA Declines Ivonescimab Approval in EGFR+ NSCLC Over Survival DataThe FDA declined to approve ivonescimab plus chemotherapy after EGFR TKI therapy, citing no statistically significant OS gain in HARMONi.Read more